TAIJI GROUP(SH:600129) Zheng Quan Zhi Xing·2025-07-07 05:39Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) is facing significant challenges with Taiji Group, which has experienced a dramatic decline in performance after a strong 2023, with a 20.72% drop in revenue and a 96.76% plunge in net profit in 2024 [1][3][9] Financial Performance - In 2024, Taiji Group's total revenue decreased by 20.72% to 12.386 billion yuan, while net profit fell by 96.76% to 26.6527 million yuan [1][3] - The company's net profit for 2024 was revised to reflect a 96.76% decline, significantly impacted by tax liabilities from subsidiaries [9][10] - Quarterly performance showed a severe drop in net profit, particularly in Q4, which contributed to the overall annual decline [4][5] Product Performance - Key products like Huoxiang Zhengqi Oral Liquid saw a sharp decline in sales, with 2024 sales volumes dropping to 96 million boxes from 231 million boxes in 2023 [8] - Other products also experienced significant sales declines, while only a few, such as sinusitis oral liquid, showed growth [8] Management and Governance - Recent personnel changes in the board of directors, with several resignations and new appointments from Sinopharm Group, indicate a shift in management strategy [5][6] - The effectiveness of the new management in reversing the company's fortunes remains uncertain as the deadline for resolving industry competition issues approaches [10] Strategic Challenges - The company is struggling with an aging product portfolio and has not introduced new blockbuster drugs in over a decade, relying heavily on existing products [8] - The upcoming deadline for Sinopharm Group's commitment to resolve competition issues poses additional pressure on Taiji Group to meet its revenue targets for the 14th Five-Year Plan [10]